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Abstract
Background:  Fenoldopam mesylate, a selective dopamine1-receptor agonist, is used by
intravenous infusion to treat hypertension in adults. Fenoldopam is not approved by the FDA for
use in children; reports describing its use in pediatrics are limited. In a multi-institutional, placebo
controlled, double-blind, multi-dose trial we determined the pharmacokinetic (PK) and
pharmacodynamic (PD) characteristics and side-effect profile of fenoldopam in children.
Methods: Seventy seven (77) children from 3 weeks to 12 years of age scheduled for surgery in
which deliberate hypotension would be induced were enrolled. Patients were randomly assigned
to one of five, blinded treatment groups (placebo or fenoldopam 0.05, 0.2, 0.8, or 3.2 mcg/kg/min
iv) for a 30-minute interval after stabilization of anesthesia and placement of vascular catheters.
Following the 30-minute blinded interval, investigators adjusted the fenoldopam dose to achieve a
target mean arterial pressure in the open-label period until deliberate hypotension was no longer
indicated (e.g., muscle-layer closure). Mean arterial pressure and heart rate were continuously
monitored and were the primary endpoints.
Results: Seventy-six children completed the trial. Fenoldopam at doses of 0.8 and 3.2 mcg/kg/min
significantly reduced blood pressure (p < 0.05) during the blinded interval, and doses of 1.0–1.2
mcg/kg/min resulted in continued control of blood pressure during the open-label interval. Doses
greater than 1.2 mcg/kg/min during the open-label period resulted in increasing heart rate without
additional reduction in blood pressure. Fenoldopam was well-tolerated; side effects occurred in a
minority of patients. The PK/PD relationship of fenoldopam in children was determined.
Conclusion:  Fenoldopam is a rapid-acting, effective agent for intravenous control of blood
pressure in children. The effective dose range is significantly higher in children undergoing
anesthesia and surgery (0.8–1.2 mcg/kg/min) than as labeled for adults (0.05–0.3 mcg/kg/min). The
PK and side-effect profiles for children and adults are similar.
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Background
Depression of systemic arterial pressure, or deliberate
hypotension, is desirable in selected patients during sur-
gery. Deliberate hypotension helps reduce bleeding,
thereby improve surgical conditions; decreases the need
for blood transfusions; and may prevent organ injury
caused by hypertension during periods of acute physio-
logic stress [1,2]. Several pharmacologic agents have been
used to control blood pressure during surgery in children,
including inhalation anesthetics, direct-acting vasodila-
tors (e.g., sodium nitroprusside, nitroglycerin) [3,4], cal-
cium channel-blockers (nicardipine) [3], and beta-
adrenergic antagonists (esmolol, labetalol) [5].
Fenoldopam mesylate is a rapid-acting vasodilator used to
manage hypertension in adults [6]. It is a selective
dopamine1-receptor agonist, producing vasodilation of
the renal, mesenteric, peripheral, and coronary arteries
[7]. Therapeutic doses increase renal blood flow, creati-
nine clearance, urinary flow, and excretion of sodium.
Fenoldopam has no significant affinity for dopamine2
receptors. In adults, steady-state plasma concentrations
are achieved rapidly, and they are proportional to infu-
sion rate. Plasma concentrations and clinical effects dissi-
pate quickly in adult patients, once the infusion is
discontinued [8]. Fenoldopam has also been shown to
control blood pressure in adult patients with hypertensive
emergencies and in the postoperative period.[9] However,
data are limited on the use of fenoldopam in pediatric
patients [10].
This study was performed to define the pharmacokinetics
(PK), pharmacodynamics (PD) and side-effect profile of
fenoldopam in pediatric patients undergoing surgery.
Methods
Our study was a randomized, multicenter, placebo-con-
trolled, dose-ranging, two-phase study. The protocol,
designed with consultation from the United States Food
and Drug Administration (FDA), was approved by the
Institutional Review Board from each participating insti-
tution. Written informed consent, and patient assent,
when applicable, were obtained.
The initial blinded, placebo-controlled, dose-ranging
phase was followed by an open-label, dose-titration
phase. Children up to 12 years of age and Tanner Stage 1
or 2 for whom deliberate hypotension was planned for at
least 2 hours during surgery were eligible for enrollment.
Surgical cases included posterior spinal fusion and other
major orthopedic, craniofacial and neurosurgical proce-
dures. Exclusion criteria included weight < 2 kg, allergy to
fenoldopam or its metabolites (e.g., sulfite or metabi-
sulfite), and contraindication for the use of dopaminergic
agents (e.g., known history of glaucoma, existing or pro-
jected development of intracranial hypertension).
Patients were randomized in equal proportions to 1 of 5
blinded infusion-treatment groups: placebo or
fenoldopam 0.05, 0.2, 0.8 or 3.2 mcg/kg/min, adminis-
tered as a continuous iv infusion for 30 minutes. After 30
minutes of blinded study-drug administration, an open-
label fenoldopam titration period was initiated until
blood pressure control was achieved.
Anesthesia was induced with propofol, sevoflurane, or
halothane as determined by the clinician. Muscle relaxa-
tion, if required, was achieved with either vecuronium or
cisatracurium. Fentanyl was used for analgesia. The
choices of drugs used for anesthetic maintenance, neu-
romuscular blockade, and analgesia were based on the
clinical needs of the individual patient, but they were kept
constant during the blinded infusion period. Blinded drug
administration (or placebo) began after stabilization of
anesthesia and placement of an arterial catheter for blood-
pressure measurement and sampling. Vital signs, includ-
ing mean arterial pressure (MAP) and heart rate (HR) were
continuously monitored and recorded just prior to drug
administration and every 5 minutes throughout the study.
Continuous electrocardiography and pulse oximetry were
also performed throughout the study.
Following 30 minutes of blinded drug or placebo admin-
istration, an open-label infusion of fenoldopam was initi-
ated at 0.1 mcg/kg/min. The dose was then titrated based
on the patient's MAP and HR response. A target MAP was
chosen for each patient such that MAP did not fall below
50 mmHg (40 mmHg for neonates). Dose adjustments
were made in increments of 0.3 to 0.5 mcg/kg/min at
intervals of at least 20 minutes to reach the target MAP. If
MAP fell below 50 mmHg (40 mmHg for neonates) or
more than 20% below the target MAP, or if HR exceeded
the age-adjusted maximum with no other explainable
cause (e.g., concomitant medication, surgical stimulation
or hemorrhage/hypovolemia), open-label fenoldopam
administration was discontinued until MAP and HR
returned to protocol limits. Fenoldopam was subse-
quently restarted at a dose 20 to 50% less than the previ-
ous dose. If discontinuation of fenoldopam for 20
minutes did not return MAP and HR to within protocol
limits, the open-label study period was terminated.
A blood sample for PK analysis was collected from all
patients 20 minutes after the start of blinded drug admin-
istration. In addition, for patients ≥ 2 years of age, blood
samples for PK analysis were collected at 5, 10, or 15 min-
utes after the start of blinded study drug administration (a
total of two samples per patient) according to a sparse
sampling protocol. Blood samples for PK analysis wereBMC Anesthesiology 2008, 8:6 http://www.biomedcentral.com/1471-2253/8/6
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also collected from all patients immediately prior to and
5 minutes after termination of open-label fenoldopam
administration. Total blood sample volumes for PK anal-
ysis were constructed by design not to exceed 1% esti-
mated blood volume for safety, so that fewer samples for
analysis were drawn from children < 2 years of age. A com-
plete blood count and chemistry panel were performed
prior to and after surgery.
PK and PD
Plasma concentrations of fenoldopam were determined
using a validated, high-performance liquid chromatogra-
phy method with mass spectrometric/mass spectrometric
detection (HPLC-MS/MS). The PK of fenoldopam was
assessed via population compartmental modeling and via
non-compartmental methods. The non-compartmental
PK variables were elimination rate constant, correspond-
ing half-life (t1/2), plasma concentration at 20 minutes
into the blinded infusion period (C20), and clearance
(CL). The elimination rate constant was estimated using
the plasma concentrations at the end of and after open-
label study drug administration, and the data were
explored for a trend with age, using linear regression anal-
ysis and tests for trend. The C20 values were used to evalu-
ate the linear kinetics of fenoldopam in pediatric patients.
The CL values were estimated by infusion rate divided rate
by C20. The pharmacokinetics parameters were estimated
with a mixed-effects non-linear fitting approach using the
program NONMEM, version V[11]
The primary PD variables were MAP and HR. NONMEM
was used to model the relationship between the PD varia-
ble (either MAP or HR) and fenoldopam plasma concen-
trations.
Onset and Offset of Effect
The time until onset of effect was determined to be the
earliest measurement of MAP during the blinded infusion
period wherein statistically significant differences
between active drug and placebo data were observed.
Time until offset of effect was calculated using the vital
sign data collected during the 30-minute interval just after
open-label study drug discontinuation. Offset was
defined as the lesser of a 10 mmHg or 10% increase in
MAP for at least 2 consecutive measurements. For patients
who failed to satisfy the above criteria during the 30 min-
utes following discontinuation of the drug, the time of
offset was assumed to be greater than 30 minutes.
Efficacy
The primary efficacy variable was MAP. An analysis of cov-
ariance was performed on the change from baseline MAP
(last measurement before the beginning of fenoldopam)
to each scheduled measurement during the blinded infu-
sion period. Within the framework of this analysis, each
fenoldopam dose was compared to placebo. In addition,
ANOVA was performed on a contrast in the treatment
effects that reflected a trend with dose, with placebo con-
sidered a 0 mcg/kg/min dose.
Side-effects
All patients administered fenoldopam were included in
the side-effects analyses. The number and percentage of
patients having drug-related adverse events were tabu-
lated by the COSTART term and body system. Each treat-
ment group was analyzed, and all groups combined were
analyzed. An analysis of covariance was performed for HR
change from baseline to each scheduled time of measure-
ment during the blinded infusion period.
Results
Demographics
Seventy-seven (77) randomized patients were enrolled.
There were 15, 15, 16, 15, and 15 patients who were
administered placebo, 0.05, 0.2, 0.8, and 3.2 mcg/kg/min
fenoldopam, respectively. One patient received no drug
due to a pump malfunction and was excluded from the
study. No statistically significant differences were
observed among the treatment groups in gender, mean
age, height, or weight (Table 1). The majority of patients
were males (56%, 43/77) and Caucasians (65%, 50/77).
The mean age was 51.9 months, with a range from 3
weeks to 12.75 years.
Study Discontinuations
The study drug was prematurely discontinued in four
patients during the blinded period. In two of these
patients receiving fenoldopam 3.2 mcg/kg/min, the drug
was discontinued because of a reduction in MAP beyond
the protocol specified limit (< 50 mmHg). The third
patient, administered placebo, and the fourth, adminis-
tered 0.2 mcg/kg/min, were discontinued because the
investigator decided the study drug was ineffective at
reducing their MAP to the target level. The study drug was
discontinued in twenty-seven patients during the open-
label period,: seven were discontinued due to adverse
events (AEs) and twenty due to other reasons (e.g., hypo-
tension no longer desired). The AEs that caused the open-
label study drug to be discontinued included hypotension
(N = 3), hemorrhage (N = 3) and tachycardia (N = 1).
Efficacy
The results of the blinded period indicated that the lowest
fenoldopam dosage that decreased MAP was 0.2 mcg/kg/
min (Figure 1). The maximum MAP decrease occurred at
a dosage of 0.8 mcg/kg/min. At the 0.8 mcg/kg/min dos-
age, statistically significant decreases in MAP compared
with placebo were seen as early as 5 minutes after initia-
tion of the fenoldopam infusion, with statistically signifi-
cant hypotensive effects also present at 15, 20, and 25BMC Anesthesiology 2008, 8:6 http://www.biomedcentral.com/1471-2253/8/6
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minutes during the 30-minute blinded infusion period.
The maximum mean decrease in MAP at the 0.8 mcg/kg/
min dosage was seen 25 minutes after initiation of the
infusion. Changes at the 3.2 mcg/kg/min dosage were
similar to those observed at the 0.8 mcg/kg/min dosage:
the maximum mean decrease was observed 25 minutes
after the start of the infusion. Statistically significant
decreases occurred at 5, 15, 20, and 25 minute time inter-
vals at the 3.2 mcg/kg/min dosage. The covariate for age
was not statistically significant with respect to change
from baseline in MAP.
Fenoldopam dosages up to 1.2 mcg/kg/min in the open-
label period caused clinically significant reductions in
MAP, but dosages greater than 1.2 mcg/kg/min conveyed
little additional benefit in lowering MAP. There appeared
Table 1: Demographic information
Fenoldopam (mcg/kg/min)
Demographic Placebo  0.05  0.2 0.8 3.2  P-valuea
Characteristic (N = 16) (N = 16) (N = 15) (N = 15) (N = 15)
Gender 0.802
Female 6 (38%) 7 (47%) 8 (50%) 5 (33%) 8 (53%)
Male 10 (63%) 8 (53%) 8 (50%) 10 (67%) 7 (47%)
Age (months) 0.917
Mean (SD) 45.6 (48.82) 60.6 (48.82) 55.9 (50.15) 49.3 (54.92) 48.2 (45.97)
Height (cm) (N = 15) (N = 13) (N = 14) (N = 14) (N = 15) 0.884
Mean (SD) 84.7 (27.59) 95.1 (32.65) 91.4 (32.17) 94.8 (34.32) 89.8 (22.24)
Weight (kg) 0.687
Mean (SD) 14.7 (9.04) 18.3 (13.55) 19.1 (14.57) 16.2 (10.95) 14.1 (7.07)
SD = standard deviation
a P-values are from a Fisher's exact test (gender and age category) or a one-way analysis of variance (age, height, weight).
Plot of means change in MAP versus time during the blind infusion period by dose Figure 1
Plot of means change in MAP versus time during the blind infusion period by dose.
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to be no loss of effect on MAP during the open-label
period of the study.
Side-effects
The average length of time that patients received
fenoldopam infusion was 3.21 hours; the range was 0.50
to 6.75 hours. The average fenoldopam dose (defined as
the cumulative dose divided by total amount of time of
study drug infusion) was of 1.00 mcg/kg/min; the range
was < 0.05 to 3.2 mcg/kg/min. The mean maximum dose
was 1.90 mcg/kg/min; the range was < 0.05 to 4.10. There
were no statistically significant differences in total infu-
sion time, average dose, or maximum dose of
fenoldopam.
Compared to patients treated with placebo, patients
treated with fenoldopam 3.2 mcg/kg/min experienced the
greatest increases in HR at all time points except at the 5-
minute time interval (Figure 2). Beginning 10 minutes
after initiation of the infusion, HR values exceeded base-
line at every time interval in the 3.2 mcg/kg/min dosing
group. Mean increases ranged from 9 to 17 bpm, achiev-
ing statistical significance at 10, 25, and 30 minutes. Mean
HR also increased at the 0.8 mcg/kg/min dosage, achiev-
ing statistical significance only at the 25-minute time
interval. When the HR across each time interval was exam-
ined, the p-value for the trend indicated a statistically sig-
nificant, dose-related increase at 10, 20, 25, and 30
minutes. Age was not found to be a statistically significant
covariate in the analysis of change from baseline in HR.
Other than tachycardia, most AEs were considered to be
unrelated to the use of fenoldopam. Four patients during
the blinded period, 13 during the open-label period, and
one during the follow-up period experienced one or more
drug-related AEs. A summary of all AEs possibly or prob-
ably related to study drug is shown is Table 2. Hypokale-
mia, an AE observed with fenoldopam administration in
the adult population [12], was observed in 7 of 76 pediat-
ric patients; only one event was considered by the investi-
gator to be possibly related to the study drug, with most
cases attributed to inadequate replacement of potassium
in IV fluids. No statistically significant differences were
observed between any of the fenoldopam dose groups
and the placebo group in mean change from baseline to
final value in any hematology or chemistry parameter.
Only one AE was reported during the follow-up period
(oliguria).
Plot of mean change in HR versus time during the blind infusion period by dose Figure 2
Plot of mean change in HR versus time during the blind infusion period by dose.
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Pharmacokinetic/Pharmacodynamic Analyses
The pharmacokinetics of fenoldopam as assessed by the
C20 values were linearly related to dose. The means ±
standard errors for the elimination rate constant and CL
values from the non-compartmental analyses were 12.4 ±
0.10 L/h and 3.02 ± 0.04 L/h/kg, respectively. The effect of
age on the elimination rate constant was not significant.
The results of the compartmental PK analysis were con-
sistent with the results from the non-compartmental anal-
ysis. A single-compartment model adequately described
the plasma-concentration data with population central
value estimates ± approximate standard errors for the
elimination rate constant and CL of 13.2 ± 1.23 h-1 and
3.06 ± 0.62 Lh-1kg-1, respectively. The effect of age on the
elimination rate constant was not significant in the com-
partmental PK analysis.
The population PK/PD modeling results indicate that the
relationship between fenoldopam plasma concentrations
and MAP is not linear; the greatest deviation from linear-
ity was found at the highest plasma levels. The maximum
effect model was found to be the best fitting model. Aver-
age population estimates ± approximate standard errors
for the maximum obtainable effect (Emax) and the plasma
concentration required to obtain half of this effect (EC50)
were found to be -27 ± 5.4 mmHg and 9.1 ± 4.23 ng/mL,
respectively. These results coincide with the observation
that dosages greater than 1.2 mcg/kg/min conveyed little
additional benefit with regard to lowering MAP. Covari-
ates for both age and baseline MAP were considered in the
Emax model, but only baseline MAP was found to signifi-
cantly enhance the model fit.
Population PK/PD modeling for HR indicates that plasma
concentrations and HR are linearly related. The estimates
± approximate standard errors of the intercept and slope
for this relationship were found to be 39 ± 6 bpm and
0.24 ± 0.05 bpm/ng/mL, respectively. Baseline HR was a
significant covariate in the model, but age was not signif-
icant.
Onset/Offset of Effect
Since statistically significant differences in change from
baseline in MAP were observed between the 0.80 mcg/kg/
min dose group and the placebo dose group as early as 5
minutes into the blinded infusion period, it is concluded
that onset of effect is approximately 5 minutes. The
median time required after discontinuation of open-label
study drug to increase MAP by the lesser of 10 mmHg or
10% for at least two consecutive measurements was 19
minutes. Therefore the time-to-offset of effect is estimated
to be approximately 19 minutes. Because this estimate is
constrained by our requirement of 2 consecutive measure-
ments at 5 minute intervals, it may be an overestimate.
Using the parameter estimates from the population PK/
PD model fit, the onset and offset of effect were calculated
to be 4.0 and 15.8 minutes, respectively.
Discussion
Fenoldopam mesylate is a selective dopaminergic1 recep-
tor agonist used as an antihypertensive drug in adult
patients. Administered via continuous intravenous infu-
sion, fenoldopam vasodilates the splanchnic and renal
vasculature, decreases blood pressure, maintains or aug-
ments renal blood flow and increases creatinine clearance.
There are limited published data however, describing the
use of fenoldopam in children. This study was designed to
evaluate the PK and PD as well as the side-effect profile of
fenoldopam during deliberately induced hypotension in
pediatric patients. Acknowledging earlier published expe-
rience with fenoldopam in pediatric patients, wherein
effective doses were reported above the package insert
label (0.05–0.3 mcg/kg/min in adults), the trial design
was selected to encompass a range of 0 – 3.2 mcg/kg/min
[10] The study design met FDA requirements for approval
of the use of fenoldopam in children and, following com-
Table 2: Incidence of Drug-related Adverse Event by COSTART terma
Blinded Period Open-Label Period Follow-Up Period
Fenoldopam Fenoldopam 
0.05 3.2  Fenoldopam Fenoldopam[PR2]
Adverse mcg/kg/min mcg/kg/min [PR1](N = 74) (N = 77[PR3])
Events (N = 15) (N = 15)
OVERALL 1 (7%) 3 (20%) 13 (17%) 1 (1%)
Hypotension 1 (7%) 3 (20%) 9 (12%) 0
Tachycardia 0 0 2 (3%) 0
Bradycardia 0 0 1 (1%) 0
Hemorrhage 0 0 1 (1%) 0
H y p o k a l e m i a 001  ( 1 % ) 0
Oliguria 0 0 0 1 (1%)
a Adverse events considered by the investigator to be possibly or probably related to study drug.BMC Anesthesiology 2008, 8:6 http://www.biomedcentral.com/1471-2253/8/6
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pletion of the trial, the FDA accepted the study data in
support of its determination of effectiveness of
fenoldopam and pediatric labeling.[13]
Seventy-six prepubertal children ≤ 12 years of age who
required deliberately induced hypotension for at least 2
hours during surgery were studied. We found that
fenoldopam 0.2 mcg/kg/min was the lowest dosage at
which decreases in BP were seen, and 0.8 mcg/kg/min was
the most effective dosage in achieving desired decreases in
BP. No additional decrease in BP was observed as the infu-
sion was increased to 3.2 mcg/kg/min, while heart rate
was significantly elevated at this dosage. The lack of fur-
ther hypotensive response at doses higher than 0.8 mcg/
kg/min may be due to the reflex tachycardia induced by
higher doses. Fenoldopam does not have dopamine2 or
beta adrenergic receptor activity, but it does produce
reflex-mediated increases in heart rate and cardiac index.
Weber et al reported that compensatory tachycardia asso-
ciated with the administration of fenoldopam and other
antihypertensive agents can offset the decrease in blood
pressure associated with a reduction in systemic vascular
resistance that these drugs produce [7].
The maximum effects model for MAP significantly out-
performed the linear model with estimates of the maxi-
mum (in magnitude) obtainable change from baseline in
MAP and the plasma concentration required to obtain
half this effect (27 ± 5.4 mmHg and 9.1 ± 4.23 ng/mL,
respectively). Although no corresponding limit to the
obtainable reduction in BP has been observed in the adult
population, the higher dosages in this study far exceeded
the maximum doses used to establish the efficacy and PK/
PD relationship in adults [14]. It is plausible that with
doses comparable to those used in this study a similar pla-
teau effect may be detectable in adults.
The intravenous administration of fenoldopam in pediat-
ric patients was well-tolerated. No increased incidence of
any AE was noted among children treated with
fenoldopam relative to adults in the relatively short dura-
tion of infusion during anesthesia. However, no behavio-
ral or subjective complaints (e.g. headache, dizziness, or
orthostatic symptoms) would have been noted in our
study, because patients were under general anesthesia.
Unlike MAP, there was no identifiable upper limit to the
change from baseline in HR seen in either the efficacy
evaluation or the PK/PD modeling. Proportional
increases in HR were seen even at the highest blinded
infusion dose level of 3.2 mcg/kg/min, and the popula-
tion PK/PD relationship was best described by a linear
relationship between plasma concentration and change
from baseline in HR. The population estimates ± approx-
imate standard errors for the added elevation of HR
(bpm) for each additional unit (ng/mL) of fenoldopam
mesylate found in plasma are 0.261 ± 0.10 and 0.501 ±
0.11 for pediatrics and adults, respectively. These esti-
mates are very similar relative to their respective variances.
Both the compartmental population estimates and non-
compartmental estimates of the elimination rate constant,
corresponding half-life, and clearance for pediatric
patients were consistent with estimates in their well-estab-
lished adult counterparts. The pediatric elimination rate
constant estimates from compartmental modeling and
non-compartmental methods were 13.2 ± 1.23 h-1 and
12.4 ± 0.10 h-1, respectively. These values correspond to
half-lives of 3.15 minutes for the compartmental estimate
and 3.35 minutes for the non-compartmental estimate.
Weight-adjusted clearance values from the compartmen-
tal modeling and non-compartmental methods were 3.06
± 0.62 L/h/kg and 3.02 ± 0.04 L/h/kg, respectively. These
values are remarkably close to the adult values for the
elimination rate constant (9.05 ± 1.21 h-1) and CL (1.66
± 0.42 L/h/kg) relative to their respective variances. On
the basis of the central value estimate of CL (3.06 L/h/kg),
approximately 0.5 mcg/kg/min of fenoldopam would
have to be infused to a pediatric patient to achieve 10 ng/
mL steady-state concentration of fenoldopam. From the
PK/PD model results, this plasma concentration is only
slightly larger than the level (9.1 ng/mL) required to attain
half the maximum (in magnitude) BP control (approxi-
mately a -13.5 mmHg reduction from baseline in MAP).
This plasma concentration is also associated with an
increase from baseline in HR of approximately 5 bpm
based upon the PK/PD model results.
The effect of age was not significant for any of the PK, PD
or side-effect profile evaluations. The dose range studied
demonstrates that although fenoldopam is highly effec-
tive in children, there is no additional benefit with respect
to blood pressure control with doses greater than 1.2 mcg/
kg/min.
A variety of pharmacologic agents have been used to
induce controlled hypotension in pediatric patients,
including inhalation anesthetics, remifentanil, vasodila-
tors, calcium channel-blockers, and beta-adrenergic
antagonists. Advantages of inhalation anesthetics include
their immediate availability in the operating room, ease of
administration, and familiarity among anesthesiologists
[15,16]. Disadvantages include myocardial depression,
interference with evoked potential monitoring, and
delayed offset following prolonged administration.
Remifentanilhas been used for controlled hypotension in
children, but no dose-response data are available [17].
Sodium nitroprusside, a potent arterial vasodilator com-
monly used in children, has a rapid onset and offset [3].
Its disadvantages include potential cyanide and thiocy-BMC Anesthesiology 2008, 8:6 http://www.biomedcentral.com/1471-2253/8/6
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anate toxicity, photodegradation, reflex tachycardia,
impaired cerebral autoregulation, and rebound hyperten-
sion [18]. In a comparative study in adults, hypotension
necessitated treatment withdrawal in a greater proportion
of patients treated with sodium nitroprusside than
fenoldopam [19]. Nitroglycerin is a direct-acting vasodila-
tor that acts primarily on venous and secondarily on arte-
rial smooth muscle. Toxicity associated with nitroglycerin
is rare, although tachyphylaxis has been shown [20].
Nitroglycerin is less effective than nitroprusside for pro-
ducing hypotension in children [4]. Nicardipine, a cal-
cium channel antagonist, has an intermediate onset and
duration of effect on blood pressure [16]. Its disadvan-
tages include its long elimination half-life precluding
rapid titration, reflex tachycardia, its interaction with
inhalation anesthetic agents, and its potentiation of neu-
romuscular blockade [21,22]. In a study of adult patients
with hypertension following CABG surgery, fenoldopam
was found to be significantly more effective than nica-
rdipine in decreasing mean arterial pressure [23]. Unlike
sodium nitroprusside, nitroglycerin, and nicardipine,
fenoldopam has been found to be regionally specific and
does not elicit cerebral vasodilation [24]. This profile may
be advantageous in situations where cerebral vasodilation
is undesirable. Esmolol, a beta-adrenergic antagonist with
rapid onset and short duration of action decreases myo-
cardial oxygen consumption and helps control coexisting
tachycardia, but it may cause excessive impairment of car-
diac output in infants and must be used with caution in
patients with a history of bronchospasm [25].
There are several limitations to this study. First, the anes-
thetic technique was not standardized due to the variety of
surgical procedures performed and the number of institu-
tions involved in the study. Second, newborns and adoles-
cents beyond Tanner Stage II maturity were excluded.
Although it may be assumed that adolescents respond to
a novel agent as do adults, this assumption has not been
sufficiently studied to provide specific recommended dos-
ing ranges in this population. Third, although we
observed no tolerance or tachyphylaxis to fenoldopam in
this study, it remains unknown whether longer-term
administration will result in tolerance or rebound hyper-
tension. If longer-term control of blood pressure is
required, it would be reasonable to initiate a longer acting
agent while reducing the dose of fenoldopam until use of
long-term infusions has been studied. Fourth, pediatric
patients with chronic hypertension, many of whom may
be receiving concomitant antihypertensive agents, were
not studied. Fifth, children with significant hepatic or
renal dysfunction were not studied. Finally, physiologic
endpoints were limited to blood pressure and heart rate,
and we did not assess regional alterations in blood flow.
Whether any specific regional tissue was rendered
ischemic (from limited blood flow secondary to lowered
blood pressure) or edematous (from excessive blood flow
secondary to regional vasodilation) was not determined.
Conclusion
In summary, fenoldopam is a unique vasodilator with
effective antihypertensive activity in children. We have
described the pharmacokinetics and pharmacodynamics
of fenoldopam in the pediatric population. For pediatric
patients it is estimated that the time of onset of effect for
fenoldopam is between 4 and 5 minutes after initiation of
IV infusion and that the time of offset of effect is between
16 and 19 minutes after termination of IV infusion. The
effective range, when given with anesthesia, was between
0.2 and 0.8 mcg/kg/min, with administration of higher
doses resulting in tachycardia without a further reduction
in MAP. No tachyphylaxis was seen in this study. Experi-
ence with longer infusions will be necessary to determine
if tolerance develops.
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